Date: 2015-05-13
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Stallergenes (France) now Ares Allergy Holding (UK)
Product: house dust mite sublingual immunotherapy tablet (STG320)
Action
mechanism: immunotherapy product
Disease: house dust mite-associated allergic rhinitis
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country: France, USA
Trial
details: The study will assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis. (NCT02443805)
Latest
news:
